Mechanistically, melatonin upregulates the core clock protein BMAL1, which transcriptionally represses its downstream target ALDH3A1, thereby effectively blocking the glycolytic program in tumor cells and suppressing cancer progression. The gene discussed is ALDH3A1; the disease is neoplasm.